206 related articles for article (PubMed ID: 38792122)
1. Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma.
Wu KY; Wang XC; Anderson M; Tran SD
Molecules; 2024 May; 29(10):. PubMed ID: 38792122
[TBL] [Abstract][Full Text] [Related]
2. Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug.
Shree D; Patra CN; Sahoo BM
Pharm Nanotechnol; 2024; 12(3):229-250. PubMed ID: 37587812
[TBL] [Abstract][Full Text] [Related]
3. Applications of nanosystems to anticancer drug therapy (Part II. Dendrimers, micelles, lipid-based nanosystems).
Ruiz ME; Gantner ME; Talevi A
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):99-128. PubMed ID: 23578193
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
[TBL] [Abstract][Full Text] [Related]
5. Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics.
Datta D; Priyanka Bandi S; Colaco V; Dhas N; Siva Reddy DV; Vora LK
Int J Pharm; 2024 Jun; 658():124192. PubMed ID: 38703931
[TBL] [Abstract][Full Text] [Related]
6. Management of retinoblastoma: opportunities and challenges.
Bhavsar D; Subramanian K; Sethuraman S; Krishnan UM
Drug Deliv; 2016 Sep; 23(7):2488-2496. PubMed ID: 25758593
[TBL] [Abstract][Full Text] [Related]
7. A Mini-review on New Developments in Nanocarriers and Polymers for Ophthalmic Drug Delivery Strategies.
Sharma Y; Patel P; Kurmi BD
Curr Drug Deliv; 2024; 21(4):488-508. PubMed ID: 37143264
[TBL] [Abstract][Full Text] [Related]
8. Nanocarriers Based Ocular Therapeutics: Updates, Challenges and Future Prospectives.
Kaushal U; Kaur M; Nagpal M; Bhuyan M; Gounder KP
Curr Drug Res Rev; 2023; 15(1):15-28. PubMed ID: 36100986
[TBL] [Abstract][Full Text] [Related]
9. Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective.
Qamar Z; Qizilbash FF; Iqubal MK; Ali A; Narang JK; Ali J; Baboota S
Recent Pat Drug Deliv Formul; 2019; 13(4):246-254. PubMed ID: 31884933
[TBL] [Abstract][Full Text] [Related]
10. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
Durgun ME; Güngör S; Özsoy Y
J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
[TBL] [Abstract][Full Text] [Related]
11. Dendrimeric systems and their applications in ocular drug delivery.
Yavuz B; Pehlivan SB; Unlü N
ScientificWorldJournal; 2013; 2013():732340. PubMed ID: 24396306
[TBL] [Abstract][Full Text] [Related]
12. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
Srinivasarao DA; Lohiya G; Katti DS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
[TBL] [Abstract][Full Text] [Related]
13. Drug delivery to the eye: what benefits do nanocarriers offer?
Joseph RR; Venkatraman SS
Nanomedicine (Lond); 2017 Mar; 12(6):683-702. PubMed ID: 28186436
[TBL] [Abstract][Full Text] [Related]
14. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
Wang R; Gao Y; Liu A; Zhai G
J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
[TBL] [Abstract][Full Text] [Related]
15. Nano-ophthalmology: Applications and considerations.
Kamaleddin MA
Nanomedicine; 2017 May; 13(4):1459-1472. PubMed ID: 28232288
[TBL] [Abstract][Full Text] [Related]
16. Dendrimer nanoparticles for ocular drug delivery.
Kambhampati SP; Kannan RM
J Ocul Pharmacol Ther; 2013 Mar; 29(2):151-65. PubMed ID: 23410062
[TBL] [Abstract][Full Text] [Related]
17. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions.
Lalu L; Tambe V; Pradhan D; Nayak K; Bagchi S; Maheshwari R; Kalia K; Tekade RK
J Control Release; 2017 Dec; 268():19-39. PubMed ID: 28756272
[TBL] [Abstract][Full Text] [Related]
18. Multi-Functionalized Nanomaterials and Nanoparticles for Diagnosis and Treatment of Retinoblastoma.
Arshad R; Barani M; Rahdar A; Sargazi S; Cucchiarini M; Pandey S; Kang M
Biosensors (Basel); 2021 Mar; 11(4):. PubMed ID: 33810621
[TBL] [Abstract][Full Text] [Related]
19. Ophthalmic nano-bioconjugates: critical challenges and technological advances.
Sanap SN; Bisen AC; Agrawal S; Kedar A; Bhatta RS
Ther Deliv; 2023 Jul; 14(7):419-441. PubMed ID: 37535389
[TBL] [Abstract][Full Text] [Related]
20. Fibrin sealant for retinoblastoma: where are we?
Martin NE; Kim JW; Abramson DH
J Ocul Pharmacol Ther; 2008 Oct; 24(5):433-8. PubMed ID: 18788992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
